The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Call for Proposals: Accelerate and promote responsible introduction of new DR-TB drugs and regimens
Unitaid is pleased to announce this call for proposals aimed at maximizing the number of people cured from drug-resistant TB by supporting introduction and scale-up of new treatment regimens. This must be done in the context of quality care that takes into account people-centered approaches, community-driven demand creation, and innovative case-finding. Interventions should promote practices to optimize access while deterring antimicrobial resistance (AMR).
Under this call, Unitaid is soliciting proposals to accelerate and expand access to BPaL/M and – subject to available evidence and inclusion in WHO recommendations – other shorter regimens in the pipeline within a quality package of care (drug-susceptibility testing, digital technology and adherence support, and safety monitoring/pharmacovigilance) by supporting demand creation and generation activities and innovative strategies for case finding while combating AMR.
Through this Call for Proposals, Unitaid aims to reduce DR-TB cases and deaths by effectively treating DR-TB disease and breaking the chain of transmission and in particular:
- To contribute to facilitating the implementation of the better shorter regimens for DR-TB in the context of a more comprehensive and supportive approach that will support sustained effectiveness of current tools while creating the environment for new tools;
- To generate demand and increase the accelerated adoption and use of these tools for DR-TB in LMICs;
- Generating real-world experience regarding optimal strategies and delivery models for implementation, case-finding and resistance monitoring
The closing date for receipt of full proposals is Wednesday 10 January 2024 at 12:00 (noon) CET.
Areas of Interest
Multi-country and regional product introduction and implementation support for the shorter DR-TB regimens and supportive tools defined as part of a quality care package to drive demand and expand access to the maximum number of people with DR TB. Geographical focus is LMICs with consideration of burden of TB, and specifically DR TB.
Proposals should include at least one of the areas  of work listed below.
- Area 1: interventions encompassing community-led strategies for stimulating demand while simultaneously advancing human rights, equity, and quality of services within the national TB programs and where feasible the broader health systems and private sector with a focus on:
- Raising awareness and building capacity of communities to drive demand creation
- Developing community-led monitoring, training, advocacy and communication tools and networks that ensure appropriate and tailored materials for different stakeholders (i.e., communities, health providers, local governments, etc.) including translation.
- Conducting coordinated campaigns at global, regional, national, and subnational levels that promote uptake, access, and awareness of a comprehensive package of care
- Establishing greater accountability nationally based on WHO’s Multisectoral Accountability Framework and the commitments set forth in the UN HLM on Tuberculosis in 2023.
- Strengthening linkages and referral networks with other relevant programs and sectors to increase and maximize the reach of TB tools and services beyond national TB programs
- Area 2: Interventions to support countries in implementing innovative and targeted strategies for enhancing quality of TB services and care, case-finding and/or resistance monitoring considering:
- Sub-national tailoring of implementation across the public and private sectors with consideration of faster, sustainable scale-up
- Approaches for diverse country contexts determining feasibility, cost-effectiveness, and willingness
- Measures and policies to broaden access to lifesaving medicines, while safeguarding long-term efficacy of key TB medicines that could have implications for AMR more broadly